Skip to content

A multicentre study of GDF-15 for early diagnosis and prognostic assessment of acute coronary syndrome

A multicentre study of GDF-15 for early diagnosis and prognostic assessment of acute coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059575
Enrollment
Unknown
Registered
2022-05-04
Start date
2022-07-01
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome (ACS)

Interventions

Gold Standard:Diagnostic criteria for acute coronary syndrome.
Index test:GDF-15 combined with traditional cardiovascular markers cTnT, D-dimer, NT-proBNP and CK-MB were used for the diagnosis and differential diagnosis of acute coronary syndrome

Sponsors

The General Hospital of the People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.ACS group: (1) Aged >=18 years; (2) Suspected or confirmed ACS patients according to the guidelines for rapid Emergency Diagnosis and Treatment of acute coronary Syndrome (2019); (3) Meeting ACS diagnostic criteria; (4) Agree and sign informed consent. 2. Non-ACS group: (1) Aged >=18 years; (2) Patients with acute chest pain and exclusion of acute coronary syndrome, such as the diagnosis of major arterial dissection (AD) according to the Chinese Expert Consensus on the diagnosis and Treatment of aortic dissection (2017 edition); Acute pulmonary thromboembolism (PTE) was diagnosed according to the European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute pulmonary thromboembolism (2019 edition); (3) Meeting the diagnostic criteria for aortic dissection; (4) Meet the diagnostic criteria for acute pulmonary embolism; (5) Agree and sign informed consent. 3. Other unidentified patients with acute chest pain: (1) Aged >=18 years; (2) Agree and sign the informed consent. 4. Healthy control group: (1) Aged >=18 years; (2) No history of cardiovascular disease; (3) Agree and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Recent history of surgery and intracranial hemorrhage; 2. Complicated with malignant tumor; 3. A history of diabetes; 4. Fever, acute or chronic inflammatory diseases in the past 2 months; 5. Patients with blood disorders, coagulation disorders and autoimmune diseases; 6. Accompanied by liver and kidney dysfunction, infectious diseases; 7. Congenital cardiovascular system diseases, cardiogenic shock, serious heart failure, etc.; 8. Systolic blood pressure >=180 mmHg and failure to take antihypertensive drugs on time.

Design outcomes

Primary

MeasureTime frame
Growth Differentiation Factor15;Cardiac Troponin T;D-Dimmer;NT-pro Brain Natriuretic Peptide;

Secondary

MeasureTime frame
Creatine Phosphokinase Isoenzyme;Blood Glucose;Ultrasound Cardiogram;CT Pulmonary Arteriography;Electrocardiogram;

Countries

China

Contacts

Public ContactZhu Haiyan

The General Hospital of the People's Liberation Army

xiaoyanzibj301@163.com+86 13521361644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026